-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_disposition-comments.pdf
September 01, 2011 - responses to the comments are posted for
public viewing on the EHC Program Web site approximately 3 months … flare during the double-blind component of the
study and who were reintroduced to etanercept up to 4 months … For balance, Amgen
recommends that the following sentence be added: “After 12 months
of treatment, … be added: “Of the 10 patients enrolled in the
etanercept arm of the trial, 1 failed to complete 12 months … Of the 14 patients enrolled
in the infliximab arm, 5 patients failed to complete 12 months – 4
because
-
effectivehealthcare.ahrq.gov/sites/default/files/data-points_1_diabetic-foot-ulcers_data_02-2011.pdf
January 01, 2011 - Fee-for-Service Cohort Population (Millions),
2007
Algorithm
Period of
Continuous
Enrollment
(Months
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/bimp-protocol.pdf
September 27, 2022 - The disposition of comments
for systematic reviews and technical briefs will be published 3 months after
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/bereaved-persons-protocol.pdf
June 01, 2023 - individuals develop complicated grief or grief with a
high level of distress that extends 6 to 12 months … Timing: predeath, acute, or 6-12 months post loss, and more than 1 year
post loss?
b. … Timing: predeath, acute, or 6-12 months post loss, and more than 1 year
post loss?
b. … Regarding timing, we will
differentiate predeath, acute, or 6-12 months post loss, and more than 1 year … Resilience to loss and chronic grief:
a prospective study from preloss to 18-months postloss.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/ptsd-adult-treatment-update_research-protocol.pdf
December 31, 2017 - for PTSD within 1 month of
trauma exposure, and 17.0 percent continue to meet criteria for PTSD 12 months … defined by evidence-based guidelines as receiving either appropriate
pharmacotherapy for 2 or more months … Psychodynamic therapy for PTSD would consist of weekly to biweekly sessions over a period of
several months … The disposition of comments for systematic reviews and technical
briefs will be published 3 months after
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/cognitive-decline_research-protocol.pdf
March 22, 2016 - We will require at least six months of
treatment. … Final health or patient-
centered outcomes:
Incident MCI or AD
Timing Minimum followup of 6
months … for intermediate
outcomes
Minimum followup of 6
months for intermediate
outcomes
None
Settings … Alzheimer’s disease, and incident MCI or Alzheimer’s disease
Timing For KQ1-2: Minimum followup of 6 months … The disposition of comments for systematic
reviews and technical briefs will be published three months
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypothyroidism-hyperthyroidism-screening-treatment_disposition-comments.pdf
February 01, 2012 - responses to the comments are posted for
public viewing on the EHC Program Web site approximately 3 months … consistent with experience--we all know
people or patients who in retrospect were
symptomatic for months … duration to dosage column header; on the
Nagasaki study I'm unclear whether you are saying that after 5
months … or whether the duration was 5
months for the whole study and the dose wasn't stated
We have added … as the two studies cited are problematic (one did not require
subclinical disease for at least 3 months
-
effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1412.pdf
December 01, 2014 - depending on expert comments received on interventions issued for
comment during the preceding 6 months … patients with moderate renal impairment), and had a history of at least 2 gout flares in the prior
12 months … proportion of patients receiving lesinurad achieved the sUA-level goal of less than 6.0 mg/dL
at 6 months
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/nonpharma-treatment-pain_research-protocol-amended.pdf
September 20, 2017 - 5: Primary chronic tension headache (defined as 15 or more
headache days per month for at least 3 months … • Timing:
o Duration of followup: short term (up to 6 months), intermediate term (6-12
months) … ), intermediate term (6-12
months) and long term (at least 1
year); focus on longer term (>1 year) … Trials lasting ≥ 6 months which
include a supervised intervention
followed by continued home treatment … The disposition of comments for systematic
reviews and technical briefs will be published three months
-
effectivehealthcare.ahrq.gov/sites/default/files/arcia-presentation.pdf
May 29, 2025 - Arcia-notes-Teresa
First, I'd like to acknowledge my colleagues, Dr. Sue Bakken is my mentor and
is the PI of
one of the major projects I'll be talking about today.
1
And
here you
can
also see our funding sources.
2
Today I'm going to talk about some of the opportunities that technology crea…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-provider-adherence_executive.pdf
May 01, 2013 - increase in
the change of percentage of patients treated with inhaled
steroid from baseline to 12 months … ranging from 52 percent to 104 percent;
change in prescribing over time (52 percent change over
6 months … and GP guidelines over a long
period (1990–2007), inconsistent followup periods ranging
from 3-12 months … :
81 percent) or hospitalizations (baseline: 96 percent,
6 months: 94 percent) was reported in the … : baseline: 49 percent;
6 months: 38 percent).
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_surveillance.pdf
December 31, 2013 - 12 months
Glycemic
control,
insulin
resistance,
and beta-cell
function
variables
Decrease … Exenatide +
metformin were superior to placebo + metformin in reducing HbA1c at 12
months (P < 0.05 … Significant decrease of waist circumference, and hip
circumference after 12 months (P < 0.01, and P … Glycemic
control
Improvement of HbA1c and PPG at 6 ( p < 0.05), 9 ( p < 0.01) and 12
months ( … A Similar decrease of body weight and
BMI was observed with both treatments at 12 months ( p < 0.05
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/dental-post-transplant-complications-rapid-research.pdf
May 01, 2025 - as 55% of solid
organ transplant recipients experiencing at least one infection within the first 12 months … Patients in the treatment group used the
oral mucosal protectant twice daily for three months. … Only emergency dental care should be
performed at least 3 months after transplant and when organ rejection … In fact, some guidelines suggest avoiding any dental treatment for at least three months post-
transplant … of Oral Oncology
KQ Key Question
MASCC Multinational Association of Supportive Care in Cancer
mo Months
-
effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/telehealth-during-COVID-19-amendments.pdf
April 28, 2022 - How do the characteristics of patients, providers, and health systems differ between the
first four months … the characteristics of telehealth use in the first
9
four months … of COVID-19 (March 2020 through July 2020) with telehealth use after the
first four months. … April 2022 PICOTS: Timing All KQ: the era of COVID-19
(March 2020-present)
KQ1d: During the first 4 months … The disposition of
comments for systematic reviews and technical briefs will be published 3 months after
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ped-mindfulness-protocol-amendment.pdf
February 05, 2025 - which we will aggregate into the following
intervals: 4 to <8 weeks, 8 to <12 weeks, 12 weeks to <6 months … , 6 months to <12 months, and ≥12
months since the beginning of the intervention or baseline assessment … The disposition of comments
for systematic reviews and technical briefs will be published 3 months after
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ped-mindfulness-protocol-amended.pdf
September 25, 2024 - which we will aggregate into the following
intervals: 4 to <8 weeks, 8 to <12 weeks, 12 weeks to <6 months … , 6 months to <12 months, and ≥12
months since the beginning of the intervention or baseline assessment … The disposition of comments
for systematic reviews and technical briefs will be published 3 months after
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-behavior-programs_consumer.pdf
November 01, 2016 - How often and for how many months
would I need to meet with the
trained provider?
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-adults-disposition-comments.pdf
August 07, 2018 - that alleviate depression may cause mania, hypomania, or
rapid cycling (four or more episodes in 12 months … decision to limit
inclusion of studies examining
bipolar depression treatments to a
minimum of 3 months … having a
minimum duration that allows for at
least full remission (e.g., DSM-5
defines it as two months … endures for a full 3 month
followup period and thus does not
require retreatment in less than 3
months … The authors’
decision to exclude depression trials of less than 3 months duration
is, as best I can
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/rotator-cuff-tear_executive.pdf
July 01, 2010 - The majority of patients first
undergo 6 weeks to 3 months of
nonoperative treatment, which may consist … cuff
integrity, pain, range of motion, and/or strength) and
have a minimum followup duration of 12 months … of several years are
needed; at the very least, studies should follow
patients for a minimum of 12 months
-
effectivehealthcare.ahrq.gov/sites/default/files/10_obesity_potential_high_impact_june_2012.pdf
January 01, 2012 - depending on expert comments received on interventions issued for comment during the
preceding 6 months … norepinephrine-releasing drug that was approved by FDA
in 1959 as an appetite suppressant for short-term (3 months … with a decision date set for April 17, 2012.
8
In April 2012, FDA extended the decision
date three months … Administration for inclusion in its therapeutic goods registry for treating T2DM
and obesity for up to 12 months … implantation, a mean excess weight loss of
29.8%, reduction of HbA1c from 8.4% at baseline to 7.0% after 6 months